▲ +203.86% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for CorMedix in the last 3 months. The average price target is $18.90, with a high forecast of $29.00 and a low forecast of $10.00. The average price target represents a 203.86% upside from the last price of $6.22.
The current consensus among 5 contributing investment analysts is to buy stock in CorMedix. This Buy consensus rating has held steady for over two years.
CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.